The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the South African B.1.351 variant, also known as 501Y.V2.
- CEPI is an international coalition set up to prepare for future infectious disease threats.
- It will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate, through Phase 1 development. Phase 1 trial will start in mid-year 2021.
- As part of the agreement, this funding will also support the preclinical expansion of additional multivalent vaccine candidates.
- VBI Vaccines is advancing a suite of coronavirus vaccine candidates under the VBI-2900 program, developed in collaboration with the National Research Council of Canada.
- An adaptive Phase 1/2 study of VBI-2902 is already ongoing at nine clinical sites in Canada.
- Price Action: VBIV shares are up 10.2% at $3.47 in premarket trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFinancingContractsSmall CapFDAGeneralCEPICOVID-19 Vaccine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in